|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.07.26 - 09:21
|
Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results (Business Wire)
|
|
|
Samsung Bioepis reports revenue of 847.1 billion KRW and an operating profit of 230.6 billion KRW in the first half of 2026, recording 6% year-over-year growth
Expanding direct commercialization in Europe to five products with the launch of OPUVIZ™ 40 mg/mL vial, a biosimilar to Eylea1 (aflibercept)
First to announce preliminary results from Phase 1, 3 clinical studies for SB27, a biosimilar candidate referencing Keytruda2 (pembrolizumab)
Samsung Epis Holdings continuing to secure next-generation growth engines through establishment of a global R&D hub in China
INCHEON, Korea--(BUSINESS WIRE)--#biosimilars--Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the second quarter and first half of fiscal year 2026.
“We delivered solid first-half 2026 results, achieving 6% growth year-over-year. This performance demonstrates the resilience of our biosimilar portfolio in the global market,&quo...
|
|
|
|
|
24.07.26 - 09:06
|
Samsung, LG showcase AI-era displays for humanoid robots (Digitimes)
|
|
|
Samsung Display (SDC) and LG Display (LGD) have unveiled a range of display concepts for next-generation AI applications at the 2026 Korea Display Exhibition (K-Display) in Seoul, ranging from face displays for humanoid robots and AI smart glasses to hidden or retractable in-car screens, building upon the companies' focus on OLED panels for IT applications to sketch out future use cases....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
